Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:688621's EV-to-FCF is ranked worse than 100% of 569
companies
in the Drug Manufacturers industry
Industry Median: 20.47
vs SHSE:688621: -197.66
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Beijing Sun-Novo Pharmaceutical Research Co (SHSE:688621) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Beijing Sun-Novo Pharmaceutical Research Co's PE Ratio (TTM) for today is calculated as:
Beijing Sun-Novo Pharmaceutical Research Co's share price for today is ¥57.61.
Beijing Sun-Novo Pharmaceutical Research Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1.770.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Beijing Sun-Novo Pharmaceutical Research Co EV-to-FCF Related Terms
Beijing Sun-Novo Pharmaceutical Research Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Sun-Novo Pharmaceutical Research Co EV-to-FCF Chart
Beijing Sun-Novo Pharmaceutical Research Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Beijing Sun-Novo Pharmaceutical Research Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Sun-Novo Pharmaceutical Research Co EV-to-FCF vs Drug Manufacturers Industry
Beijing Sun-Novo Pharmaceutical Research Co's current Enterprise Value is ¥6,786 Mil.
Beijing Sun-Novo Pharmaceutical Research Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-34 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Sun-Novo Pharmaceutical Research Co (SHSE:688621) has a EV-to-FCF of -201.55 as of Jul. 28, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Beijing Sun-Novo Pharmaceutical Research Co and its competitors. According to the industry distribution chart, Beijing Sun-Novo Pharmaceutical Research Co ranks #999999 out of 569 companies in the Drug Manufacturers industry.
Is Beijing Sun-Novo Pharmaceutical Research Co's EV-to-FCF too high?
Beijing Sun-Novo Pharmaceutical Research Co's current EV-to-FCF is -201.55. Based on the distribution chart, Beijing Sun-Novo Pharmaceutical Research Co ranks #999999 out of 569 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Beijing Sun-Novo Pharmaceutical Research Co has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beijing Sun-Novo Pharmaceutical Research Co's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Beijing Sun-Novo Pharmaceutical Research Co ranks #999999 out of 569 companies for EV-to-FCF. This places Beijing Sun-Novo Pharmaceutical Research Co in the lower half of its industry. The industry median EV-to-FCF is 20.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.47, based on 569 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Beijing Sun-Novo Pharmaceutical Research Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beijing Sun-Novo Pharmaceutical Research Co's current EV-to-FCF is -201.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Sun-Novo Pharmaceutical Research Co stock overvalued right now?
Based on GuruFocus' analysis, Beijing Sun-Novo Pharmaceutical Research Co (SHSE:688621) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥70.82, compared to a current price of ¥57.61 — trading 18.7% below its estimated fair value. The current EV-to-FCF is -201.55. Beijing Sun-Novo Pharmaceutical Research Co's overall GF Score™ is 93/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Beijing Sun-Novo Pharmaceutical Research Co (SHSE:688621), the current EV-to-FCF is -201.55 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Sun-Novo Pharmaceutical Research Co (SHSE:688621) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Sun-Novo Pharmaceutical Research Co stock appears to be undervalued.
The current stock price of ¥57.61 is trading 18.7% below its estimated GF Value™ of ¥70.82.
GuruFocus considers Beijing Sun-Novo Pharmaceutical Research Co to be Modestly Undervalued.
Key valuation signals for SHSE:688621:
EV-to-FCF: -201.55
GF Value™: ¥70.82 vs. price of ¥57.61 (18.7% below fair value)
No single metric tells the full story. See the SHSE:688621 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Sun-Novo Pharmaceutical Research Co Business Description
Beijing Sun-Novo Pharmaceutical Research Co Ltd is engaged in providing professional research and development outsourcing services for pharmaceutical companies.
93GF Score
Get the complete analysis for SHSE:688621
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688621 has been successfully added to your 
